Analysts have set 12-month price targets for Alkermes, revealing an average target of $38.0, a high estimate of $50.00, and a ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

The market expects Alkermes (ALKS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook is ...

Alkermes (ALKS) expects its set of proprietary products, Vivitrol, Aristada and Lybalvi, to generate incremental sales and ...

Alkermes reports positive Phase 1 results for ALKS-2680 in narcolepsy and idiopathic hypersomnia, with significant efficacy and manageable side effects. The company plans to proceed with a Phase 2 ...

Alkermes' spinoff transaction with Mural Oncology resulted in cost cutting and higher EBITDA margins, with strong 2023 profitability gains expected to continue into 2024. ALKS stock is currently ...

Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alkermes (ALKS – Research Report) and Ocular ...

DUBLIN, April 24, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 ...